Chimeric Antigen Receptor T-Cell Therapy - Medical Policy
Customize your policy alerts
Sign up for Health-New-England Policy UM699POL alerts
Get alerted when Policy UM699POL changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and site-of-service review for CAR-T therapy for Health New England Commercial, Medicare Advantage, and Medicaid (BeHealthy) members. Drug approval must be obtained through the applicable pharmacy or Medicaid utilization-review process before site-of-service review.
Universal criteria were removed from the policy in January 2026.
CAR-T procedure coding was updated from prior codes to CPT 38225 through 38228 in November 2024.
The Commercial and Medicare drug-approval process is routed through Prime Therapeutics, while Medicaid approval is routed through the MassHealth Drug Utilization Review Program.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.